Page last updated: 2024-12-06

mopidamol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Mopidamol: A phosphodiesterase inhibitor which inhibits platelet aggregation. Formerly used as an antineoplastic. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID26172
CHEMBL ID2106769
CHEBI ID135682
SCHEMBL ID9440
MeSH IDM0014050

Synonyms (31)

Synonym
mopidamol
einecs 237-145-6
brn 0587985
r-a 233-bs
compound ra-233
ra-233
rapenton
ethanol, 2,2',2'',2'''-((4-piperidinopyrimido(5,4-d)pyrimidine-2,6-diyl)dinitrilo)tetra-
ethanol, 2,2',2'',2'''-((4-(1-piperidinyl)pyrimido(5,4-d)pyrimidine-2,6-diyl)dinitrilo)tetrakis-
2,2',2'',2'''-((4-piperidinopyrimido(5,4-d)pyrimidine-2,6-diyl)dinitrilo)tetraethanol
2,2',2',2'''-((4-piperidinopyrimido(5,4-d)pyrimidine-2,6-diyl)dinitrilo)tetraethanol
mopidamolum [inn-latin]
ra 233
2,6-bis(diethanolamino)-4-piperidinopyrimido(5,4-d)pyrimidine
CHEBI:135682
2-[[2-[bis(2-hydroxyethyl)amino]-4-piperidin-1-ylpyrimido[5,4-d]pyrimidin-6-yl]-(2-hydroxyethyl)amino]ethanol
13665-88-8
mopidamol [inn:ban]
unii-4q0iwp8b8o
mopidamolum
4q0iwp8b8o ,
CHEMBL2106769
SCHEMBL9440
mopidamol [inn]
mopidamol [mi]
mopidamol [who-dd]
mopidamol [mart.]
DTXSID30159878
2,2',2'',2'''-((4-(piperidin-1-yl)pyrimido[5,4-d]pyrimidine-2,6-diyl)bis(azanetriyl))tetrakis(ethan-1-ol)
Q27260347
AKOS040747180

Research Excerpts

Treatment

ExcerptReferenceRelevance
"In mopidamole treated groups the number of animals with lung metastases was significantly decreased."( Antimetastatic effect of flurbiprofen and other platelet aggregation inhibitors.
Grimová, J; Kacerovská, H; Mamytbeková, A; Rezábek, K; Svobodová, J, 1986
)
0.78

Compound-Compound Interactions

ExcerptReferenceRelevance
"The effect of the platelet aggregation inhibitor RA233 alone or in combination with radiation was investigated on the spontaneously metastasizing B16 melanoma and on the Lewis lung carcinoma."( Effect of RA233 alone and combined with radiation on experimental tumour metastasis. Part 1.
Hellmann, K; Li, XT,
)
0.13
"The effect of RA233 alone or in combination with radiation was investigated in vivo on the S180 sarcoma, the B16 melanoma and the Lewis lung carcinoma."( Antitumor effect of RA233 alone and combined with radiotherapy.
Hellmann, K; Li, XT,
)
0.13

Dosage Studied

ExcerptRelevanceReference
" Dose-response and time-response curves were plotted for all compounds."( The pyrimido-pyrimidine derivative RA-642: a potent inhibitor of ferrous-induced lipid peroxidation in cell membranes.
Bellido, I; de la Cruz, JP; Sánchez de la Cuesta, F,
)
0.13
" Two dosing schedules were used: (a) on Days 5 through 19 and (b) on Day 5 until death."( Drug treatments for metastasis of the Lewis lung carcinoma: lack of correlation between inhibition of lung metastasis and survival.
Bemis, KG; Campbell, JB; Matsumoto, K; Merriman, RL; Shackelford, KA; Tanzer, LR, 1989
)
0.28
" RA-233 in vitro improved deformability according to a bell-shaped dose-response curve."( Studies on the vasoocclusive crisis of sickle cell disease. III. In vitro and in vivo effect of the pyrimido-pyrimidine derivative, RA-233: studies on its mechanism of action.
Ambrus, JL; Bannerman, RM; Gastpar, H; Marton, J; Meky, N; Melewski, DJ; Sharma, S; Sills, RH; Stadler, S, 1987
)
0.27
" A dose-response curve was developed for each interferon in which the maximum dose applied gave at least 30% growth inhibition of control values after 96-128 hours of continuous exposure."( The in vitro interaction of RA-233 and several interferons on human cell lines.
Harvey, HA; Leitzel, KE; Lipton, A; Wolf, LM, 1984
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
tertiary amino compoundA compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
dialkylarylamine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (71)

TimeframeStudies, This Drug (%)All Drugs %
pre-199058 (81.69)18.7374
1990's13 (18.31)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.87 (24.57)
Research Supply Index4.43 (2.92)
Research Growth Index4.30 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (7.79%)5.53%
Reviews6 (7.79%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other65 (84.42%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]